Akebia Therapeutics earnings were -$69.4M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest AKBA earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$22.8M, up 13.8% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, AKBA reported annual earnings of -$69.4M, with 33.7% growth. The next AKBA earnings date is May 7, 2025.
Akebia Therapeutics Earnings Reports & History FAQ
What were Akebia Therapeutics's earnings last quarter?
On AKBA's earnings call on Invalid Date, Akebia Therapeutics (NASDAQ: AKBA) reported Q4 2024 earnings per share (EPS) of -$0.11, up Infinity% year over year. Total AKBA earnings for the quarter were -$22.80 million. In the same quarter last year, Akebia Therapeutics's earnings per share (EPS) was $0.00.
The next AKBA earnings call is Invalid Date. Add AKBA to your watchlist to be reminded of Akebia Therapeutics's next earnings date.
Is Akebia Therapeutics profitable or losing money?
As of the last Akebia Therapeutics earnings report, Akebia Therapeutics is currently losing money. Akebia Therapeutics's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$69.41 million, a 33.67% increase year over year.
What was AKBA's earnings growth in the past year?
As of Akebia Therapeutics's earnings date in Invalid Date, Akebia Therapeutics's earnings has grown year over year. AKBA earnings in the past year totalled -$69.41 million.
What are Akebia Therapeutics's earnings expectations?
The current EPS estimate for Akebia Therapeutics's earnings report in Invalid Date is -$0.08.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.